For the year ending 2025-12-28, QDEL had $71,300K increase in cash & cash equivalents over the period. -$83,000K in free cash flow.
| Cash Flow | 2025-12-28 |
|---|---|
| Net (loss) income | -1,131,800 |
| Depreciation and amortization | 442,000 |
| Goodwill impairment charge | 700,700 |
| Asset impairment charge | 9,700 |
| Stock-based compensation expense | 45,900 |
| Change in deferred tax assets and liabilities | 6,300 |
| Payment of accreted interest on contingent and deferred consideration | 0 |
| Loss on extinguishment of debt | -5,100 |
| Asset write off related to restructuring, integration and other charges | 152,200 |
| Asset write off related to tax assessment refund | 0 |
| Other non-cash, net | 900 |
| Accounts receivable | 117,500 |
| Inventories | 148,300 |
| Prepaid expenses and other current and non-current assets | 34,600 |
| Accounts payable | 40,000 |
| Accrued payroll and related expenses | 900 |
| Income taxes payable | 41,700 |
| Other current and non-current liabilities | 92,000 |
| Net cash provided by operating activities | 105,200 |
| Acquisitions of property, plant, equipment, investments and intangibles | 188,200 |
| Proceeds from held for sale asset, net of costs to sell | 0 |
| Proceeds from government assistance allocated to fixed assets | 6,500 |
| Purchases of marketable securities | 0 |
| Proceeds from sale of marketable securities | 0 |
| Loan to lex diagnostics | 11,000 |
| Net cash used for investing activities | -192,700 |
| Proceeds from issuance of common stock | 6,100 |
| Short-term borrowings, net | 3,000 |
| Revolving credit facility, net | -118,000 |
| Proceeds from long-term borrowings, net of discount and debt issuance costs | 2,559,300 |
| Payments on long-term borrowings | 2,289,200 |
| Payments of tax withholdings related to vesting of stock-based awards | 5,400 |
| Repurchases of common stock | 0 |
| Principal payments of deferred consideration | 0 |
| Net cash provided by (used for) financing activities | 155,800 |
| Effect of exchange rates on cash | 3,000 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 71,300 |
| Cash, cash equivalents and restricted cash at beginning of period | 98,500 |
| Cash, cash equivalents and restricted cash at end of period | 169,800 |
QuidelOrtho Corp (QDEL)
QuidelOrtho Corp (QDEL)